Marijuana stocks have been less than perky of late, but Echelon Wealth Partners analyst Russell Stanley thinks Canopy Growth Corp’s (TSX:WEED) foray into the coffee market is one that underscores its leadership role in the space. This morning, Canopy announced it had entered into a licensing agreement with Swiss-based hemp company Isodiol International Inc., that […]
The Cantech Letter Cannabis section is brought to you by ABCann Medicinals. Organically grown standardized marijuana. Click on the logo above for more info.
Canopy Growth Corp still a tremendous buy despite Bedrocan legal issue, Echelon says
Arbitration proceedings surrounding its wholly owned subsidiary are a “slight negative”, but Echelon Wealth Partners analyst Russell Stanley thinks Canopy Growth Corp. (TSX:WEED) is hugely undervalued. On Friday, Canopy announced that its wholly-owned subsidiary Bedrocan Canada had commenced arbitration against Bedrocan International BV, claiming the latter had withheld services, designs and supports required by its […]
Aphria gets price target raise to $13.00 at Clarus Securities
A better than expected quarter has Clarus analyst Noel Atkinson raising his price target on Aphria (TSXV:APH). On Wednesday, Aphria reported its Q4 and fiscal 2017 results. In the fourth quarter, the company lost $2.6-million on revenue of $5.7-million, a topline that was up 106 per cent over the same period last year. “”We capped […]
Invictus MD Strategies Corp is undervalued, says Echelon Wealth
Invictus MD Strategies (TSXV:IMH) is a cannabis producer that should be on the radar of investors, says Echelon Wealth Partners analyst Russell Stanley. In a research report to clients Wednesday, Stanley initiated coverage of Invictus MD Strategies with a “Speculative Buy” rating and a one-year price target of $2.00, implying a return of 82 per […]
No Licensed Producer will capture more than 20% of cannabis supply: Canaccord Genuity
Health Canada has granted a total of 50 cultivation licenses, and Canaccord Genuity analyst Neil Maruoka thinks it is unlikely one will become dominant enough to control more than 20 per cent of the total supply. In an extensive research report on the Canadian cannabis sector yesterday, Maruoka revised his market share estimates in the […]
Here’s Canaccord Genuity’s new top pick in the cannabis space
The first mover advantage is real in the cannabis sector, but recent developments have opened the door for new entries, says Canaccord Genuity analyst Neil Maruoka. In a research report to clients this morning, Maruoka initiated coverage of three marijuana stocks; Maricann Group (CSE:MARI), Cronos Group (TSXV:MJN), and Invictus MD Strategies (TSXV:IMH). Maruoka says he […]
Canaccord Genuity cuts target on Canopy Growth Corp. after weak Q4
A softer than expected quarter has Canaccord Genuity analyst Neil Maruoka lowering his price target on Canopy Growth Corp. (TSX:WEED). On Tuesday, Canopy Growth Corp. reported its fourth quarter and fiscal 2017 results. In the fourth quarter, the company posted an Adjusted EBITDA loss of $5.3-million on revenue of $14.7-million. “With a patient base that […]
Buy Canopy Growth Corp. ahead of Q4 results, says Echelon Wealth Partners
Ahead of its fourth quarter results, Echelon Wealth Partners analyst Russell Stanley thinks investors should be buying Canopy Growth Corp. (TSX:WEED). On Tuesday, June 27, Canopy Growth Corp. will report it fourth quarter and fiscal 2017 results. Stanley thinks Canopy will post a loss of $0.08 a share and an EBITDA loss of $6.1-million on […]
Supreme Pharmaceuticals is undervalued, says Canaccord Genuity
It doesn’t yet have a sales license, but Supreme Pharmaceuticals (TSXV:FIRE) is making real progress, says Canaccord Genuity analyst Matt Bottomley. This morning, Supreme Pharamaceuticals announced it had received several updates from Health Canada regarding its cultivation licence pursuant to the access to cannabis for medical purposes regulations. Management said Health Canada was in the […]
Canopy Growth has a significant opportunity in Germany, says Canaccord Genuity
Canopy Growth Corp. (TSX:WEED) has a real chance to make a splash in the nascent German marijuana market, says Canaccord Genuity analyst Neil Maruoka. This morning, Canopy Growth issued an update, part of which was dedicated to the company’s efforts in Germany. The company will rename its German subsidiary Spektrum Cannabis Germany GmbH an said […]
- 1
- 2
- 3
- …
- 8
- Next Page »